loading...| Preferred Name |
Limonene, (+)- |
|
| Synonyms |
|
|
| Definitions |
An oral dietary supplement containing a natural cyclic monoterpene, and a major component of the oil extracted from citrus peels, with potential chemopreventive and antineoplastic activities. Upon oral administration, D-limonene activates aldehyde dehydrogenase 3A1 (ALDH3A1), thereby decreasing aldehyde level. This may protect salivary stem/progenitor cells (SSPCs) from toxic aldehydes and prevent or improve radiation-induced xerostomia. Limonene and its metabolites perillic acid, dihydroperillic acid, uroterpenol and limonene 1,2-diol may also inhibit tumor growth through inhibition of p21-dependent signaling and may induce apoptosis via the induction of the transforming growth factor beta-signaling pathway. In addition, they inhibit post-translational modification of signal transduction proteins, resulting in G1 cell cycle arrest as well as differential expression of cell cycle- and apoptosis-related genes. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C61714 |
|
| ALT_DEFINITION |
A terpene with two isoprene units forming a ring. The chemical structure is CC1=CCC(CC1)C(=C)C. |
|
| CAS_Registry |
5989-27-5 7705-13-7 |
|
| CHEBI_ID |
CHEBI:15382 |
|
| Chemical_Formula |
C10H16 |
|
| code |
C61714 |
|
| Contributing_Source |
CRCH CTRP FDA |
|
| definition |
An oral dietary supplement containing a natural cyclic monoterpene, and a major component of the oil extracted from citrus peels, with potential chemopreventive and antineoplastic activities. Upon oral administration, D-limonene activates aldehyde dehydrogenase 3A1 (ALDH3A1), thereby decreasing aldehyde level. This may protect salivary stem/progenitor cells (SSPCs) from toxic aldehydes and prevent or improve radiation-induced xerostomia. Limonene and its metabolites perillic acid, dihydroperillic acid, uroterpenol and limonene 1,2-diol may also inhibit tumor growth through inhibition of p21-dependent signaling and may induce apoptosis via the induction of the transforming growth factor beta-signaling pathway. In addition, they inhibit post-translational modification of signal transduction proteins, resulting in G1 cell cycle arrest as well as differential expression of cell cycle- and apoptosis-related genes. |
|
| Display_Name |
Limonene, (+)- |
|
| FDA_UNII_Code |
GFD7C86Q1W |
|
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 |
|
| Is_Value_For_GDC_Property | ||
| label |
Limonene, (+)- |
|
| Legacy Concept Name |
D-Limonene |
|
| Maps_To |
Limonene, (+)- |
|
| NCI_Drug_Dictionary_ID |
664042 |
|
| PDQ_Closed_Trial_Search_ID |
664042 |
|
| PDQ_Open_Trial_Search_ID |
664042 |
|
| Preferred_Name |
Limonene, (+)- |
|
| prefixIRI |
NCIT:C61714 |
|
| prefLabel |
Limonene, (+)- |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C0950252 |
|
| subClassOf |